µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ 'J?{/O ^
BdD]HXB|_
ѧ¿Æרҵ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ) ^En
p)
SW(pS
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Z:{|
?4
>
'R{,1# U
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© "}3sL#|z
]he~KO[j<
1. CD4 $UzSPhv[
A}lxJ5h0
2. T cell receptor(TCR) D W U=qD+
/bykIUTKI
3. immunoglobulin superfamily (IgSF) lc
<V_8
0)|Z7c&
4. selectin RL` jaS?V
! t!4CY
5. anti-idiotypic antibody (¦ÁId) {<{VJGY7T
9Y3"V
3EZ
6. major histocompatibility complex(MHC) 1i#y>fUj
vhF9|('G
7. immunotolerance 8oE`>Y
x{;{fMN1
8. biological reponse modifier(BRM) ug,AvHEnB
45 ^ Z5t
9. immune reponse gene (Ir gene) ]0>
y^H5iB[SPL
10. reshaped antibody (or reconstituted antibody) N7s0Ua'-v
-. *E<%
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© .'=S1|_(
~g!!#ad
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ ,6]ID1o:y
%fF,Fnf2
2. ϸ°û¶¾ÐÔTÁÜ°Íϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? L--
t(G
3u
j|jwL
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ f2c<-}wR
Y-})/zFc
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? .iV=ybMT
o1#3A
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) |"K%Tvxe
,~cK]!:>s
¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ 1)c{;x&W
9X*Z\-
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? B{\Y~>]Pj
(LsVd2AbR
2. Ä¿Ç°µ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? W!HjO;
hbYstK;]Z
¡¡ `.;U)}Tn
7[=G;2<
¹©Ïû»¯ÄÚ¿ÆרҵÊÔÌ⣺ dm/3{\ 4
"yH?df24
1. Ä¿Ç°ÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔÀíºÍ½á¹û²â¶¨? 274j7Y'
Re~6'
2. Ä¿Ç°µ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? lO\HchGzB
+E9G"Z65iP
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ,W+=N"`a'
9Pg6,[*u
ѧ¿Æרҵ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ xppnBnu$7
sR$abN+u
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ gm5%X'XL
E[t[R<v,P!
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© :C^{Lc
?
IeBo8
1. CD8 Z[[*:9rY|
b,:^\HKC
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) bX[ZVE(L
3KqRw (BK
3. immunoglobulin fold(Ig fold) +D
@B eQu
5.-:)=
4. cadherin (Ca-dependent cell adhesion moleculers) h7ZH/g$)
0X99D2c
5. idiotype-anti-idiotypic antibody immune network theory 6t!=k6`1
851BOkRal4
6. HLA class II antigen tHaHBx1P
X)(K|[
7. complementarity-determining region (CDR) ?$)a[UnqX
D4"<suU|.
8. perforin(or pore-forming protein ,PFP) F+VNrt-
"<Di
9. high affinity IL-2 receptor z( ^?xv
M'|[:I.V
10. artificial active immunization 5o{U$
8|=
c3Z
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© ~9@527m<',
\a
of
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠs`Z.H5V>\
`"'u
mIz
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 vp&.
9pi{)PDJ
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ zGme}z;1@
DB|w&tygq
4. ÊԱȽÏT¡¢BÁÜ°Íϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃ濹ԡ¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ *EO*Gg0d
(-1{W^(
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐÑ¡Ò»Ìâ,3¡¢4ÌâÖÐÑ¡Ò»Ìâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) \ eba9i^
[ Ous|a[)o
1. Ä¿Ç°¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔÀí¡£
ADxje%!1O
-1$z=,q'
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? ( +
S-
g<DXJ7o
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ Qa9@Q$
k!z.6di
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ *\+oe+ 3
V_^pPBa
¡¡ .`u8(S+
ZJFF4($qN
F;/^5T3wI
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ g;q.vHvsc"
ѧ¿Æרҵ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ /EHO(d!<
"Ar|i8^G3
¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ K5<2jl3S
B`nI]_
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© Gys-Im6>~@
;X+.Ag
1. immunoglobulin gene rearrangement f `b6E J
E@E
wx;P5
2. the common chain of cytokine receptor (or a cytokine receptor gs.+|4dv
4y4r;[@U
subunit shared by some cytokine receptors) 7N5M=f.DS(
-)&lsFF
3. flow cytometry(FCM) } nIYNeP?D
Jv%)UR.]
4. carrier effect
C>-}BeY!
J?E!\V&U
5. positive selection of T lymphocytes in thymus F}F{/
"N EKz
6. mouse TH1(Th1) and TH2(Th2) subsets lA6{TH.x
P uQ
7. perforin (pore-forming protein ,PFP) KB~`3Wj|Z
WU/5i 8
8. ADCC(antibody-dependent cell-mediated cytotoxicity) wpNb/U
8{%&P%vf
9. SH-2(src-homology region 2) %3=T7j
D4@(_6^
10. Ab2¦Â (internal image) _S*QIbO
,Cy&tRjR B
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© .345%j
=:TQ_>$Nc2
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? n"~K",~P
8@6*d.+e
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? c*(=Glzn
!0Ak)Q]e'
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦ÓᣠhsK(09:J
O|9Nl*rXz
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ |\ C.il7
:4\_upRE
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠhbx+*KM
:^x,>(a
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) f?@M"p@T
xi.QHKBZaH
ÃâÒßѧרҵ£º 0'zjPE#
gaU^l73,C
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ &Ci_wDJ
O=u.J8S2
2. ÊԱȽÏÈËT¡¢BÁÜ°Íϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? An
BM*5G
COH.`Tv{*
´«È¾²¡Ñ§×¨Òµ£º [eDRghK
Lk)TK/JM)
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦ÄÜ¿É·¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ 1aUu:#c
I
wu^@
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØϵ¡£ K=P LOC5
(+TL
]9P
Ïû»¯×¨Òµ£º 1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹ÔÑо¿µÄ½øÕ¹¡£ E_xk8X~
BK.RYS
N
2.¼òÊöճĤÏà¹ØÁÜ°ÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌص㡣·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? q}&+{dN\1
$K1)2WG
(g tOYEqx
7P52r
O-+!KXHd[
Q0""wRq'
uVw|jj
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ "W"r0"4
tqU8>d0^
ÃâÒßѧÊÔÌâ ZB,UQ~!Yr
;FjI!V
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© tQ2S*]"f
%S%0/
1. Fas(CD95)/FasL 7$:Jea
Cy
JZip
2. common chain of cytokine receptor xQzXl
@
])}+4D(S
3 . TCR/CD3 complex z|N*Gs>,
;BEX|wxn
4. negaive selection of thymocytes i#Fe`Z ~J
o@|kq1m8
5. artificial active immune ]Ai!G7s8P
fH_Xm :%
6. anti-idiotypic X^.~f+d~
<kWNx.eci
7. IgSF IpsV4nmnz-
`b[@GGv
8. Integrin <Ow+LJWQK
9!vimu)
9. chemokine G4,BcCPQ
?Q}3X-xy
10. B7/CD28 ~ZRtNL9
x@<!# d+
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© (7}Zh|@W
vb k4
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԲÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹ÔµÄ¹ý³Ì¡£ kX'a*
AG
M0uC0\'#P
2. ±È½ÏCTLºÍNKɱÉË°Ðϸ°ûʱʶ±ðºÍɱÉË»úÖƵÄÌص㡣 ~ouRDO
U{-[lpd
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô»òÖ×ÁöÏà¹Ø¿¹Ô,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆʵÑé·½°¸¿Ë¡´Ë»ùÒò¡£
8B7,qxZ
*|/kKvN
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô¡£ FGRG?d4?h
P,SI0$Z
hHqsI`7c
Kl+4A}Uo
b]5S9^=LI
4S,/Z{ J.
Z`bo1,6>
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ *XqS~G
kv?j]<WN
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© #h7$b@
7:h_U9Za?$
1. B7/CD28
J~rjI24
|0aGX]Y
2. Th1 subset <<9Y=%C+
oJ)v6"j
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© 3`Q>s;DjIU
kn7Qv
k[+
4. antibody affinity maturation u:O6MO9^
E 5bo60z
5. AP-1 Rk52K*Dc
9w,u4q
6. single chain variable fragment£¨ScFv£© ;Ajy54}7
'QEQyJ0EB
7. NK cell receptor KdTna6nY
q5(Z
8. Zinkernagel-Doherty phenomenon IpMZ{kJlv`
) "Toh=x]
9. Ig fold k34!*(`q
;Cqjg.wkB
10. CD40/CD40L W&(98}oT
1f`=U0
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© z;EnAy {9
4FgY!k
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØϵ¡£ /!Kl
P&@[ j0
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ PNM
f5'@m
Yl6\}_h`
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹Øϵ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ )z#M_[zC>
*!y.!v*
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ Q-GnNT7MB3
5=.EngG
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô¡¢ÁÜ°Íϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ 35[8XD
mjqVP.
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ C=/nZGG
D%Y{(l+X
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æרҵ£©¡£ cAE.I$T(
3yAzt*dZ
}3Y3f).ZW
@pD']=d}t
VoJelyzh
'.wyfS H@
RZ[r XV5
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ 1Bz'$u;
F W # S.<
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© Z<#beT6
O$%C(n(
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© ~4mgYzOmD`
fxQN
1.Co-stimulators (or co-stimulating molecules) j}
?O
D>O{>;y[
2.NK-kB S{NfU/:
dL
X~Li`
3.Immunoglobulin superfamily T@]vjXd![
"l&sDh%Lk<
4.antigen-presenting cell (APC) <bf^'$l
.O'gD.|^N
5.death domain m//(1hWv7
OX?9 3AlG
6.CCR and CXCR >=2nAv/(
Kk~0jP_ B9
7.Lectin (or mitogen) f#l/N%VoBZ
'B"kUh%3$5
8.Clusters of differentiation, CD) 3Nh;^
xnu|?;.}!
9.B7 family cmu5KeH
XQk9 U
10.Cytotoxic T lymphocyte, CTL) sf?D4UdIH
`ge{KB;*n#
11.IL-15 and IL-15 receptor (IL-15R) / vge@bsE
odquAqn
12.MHC restriction (G"b)"Qum
EG0NikT?
13.Affinity-chromatography UsYH#?|O
%.b)%=
14.Cyctosprin A, CsA ?S0VtHQ
8@/]ki`>
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) }qW%=;!
9\Mesf1$o
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© P7E}^y`e
slHlfWHq
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 qB7.LR*
'
qEf)TW(
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØϵ¡£ 9GkG'
$Kb-mFR
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹ÔµÄÌص㡣 >9=Y(`
q?Q"Ab
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© ` /]8C&u
A@_F ;4X
ÃâÒßѧרҵ£º E] t:_v
ez86+
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ xvjHGgWSxc
Roy`HU
;0a
Ïû»¯ÄÚ¿Æ£º Q_6./.GQ
C3bZ3vcW$
2.Ö×Áö¿¹Ô·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ 5HL JkOV5
@OFl^U0/
ѪҺ²¡Ñ§×¨Òµ£º X'jEI{1w
%nOBs ln
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎΪÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔÒò£¨Ìõ¼þ£©ÊÇʲô£¿ KzeA+PI
\E?1bc{\f
=[t( [DG
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ ui G7
yKOf]m>#
(רҵ»ù´¡: ÃâÒßѧ) ?8! 4!P%n
z=>]E1'RL
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) Ax0u \(p<^
cKF02?)TX
1. ADCC(antibody dependent cell-mediated cytotoxicity) {E6b/G?Q
I^M3>}p
2. »·æß¾úËØ(cyclosporin) !S%XIq}FX
|KU>+4
=
@
3. KIR(killer cell inhibitory receptor) TDtk'=;
yn!LJT[~2
4. HLDA(human leucocyte differentiation antigen) %>xW_5;Z
-Q 6W`*8
5. Interleukin 18(IL-18) qdZn9i
Iy|]U&`
6. ÕûºÏËØ(integrin) EW#.)@-
#1u4Hi(x5
7. Fas/FasL 4(u+YW GX
|%&WYm6
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) 1/gY]ghL
4w]u: eU
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) O~fRcf:Q
|`qur5h`
10. Th1/Th2 !p&M,6
k[Uc_=
11. »ùÒòÒßÃç(DNAÒßÃç) ,W*<e-
f} }Bb8
12. chemokines and chemokine receptor v[m/>l2[P
Lk#u^|Eq7=
13. ÃâÒßÄÍÊÜ mtm BL2?
j]Rl1~+M
14. ¹²´Ì¼¤·Ö×Ó us`hR!_
z?j~ 2K<4
15. ËÀÍö½á¹¹Óò(death domain) fB
!R{L`T0
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) Z?"Pkc.Ei
UvQxtT]
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉË°Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? ; M"hX
g[H7.
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»Æƶø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠmjBX
a
>L&>B5)9
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î QdC>fy
VCbnS191*
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ y3;G<9K2c]
z%*ZmF ^K
£¨3£©1984Ä꣺ÁÜ°Íϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå fKrOz!b
T=b5th
}
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ qr<5z. %
Rq4\~F?
3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄЩÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£